DUSSELDORF, Germany and Barcelona, Spain, March 15, 2022 /PRNewswire/ — Neuraxpharm Group (Neuraxpharm), one of Europe’s leading specialty pharma companies focused on the central nervous system (CNS), today announces that Tom Coogan was appointed Country Manager for Ireland. This appointment strengthens Neuraxpharm’s management team by Ireland with an experienced executive who will focus on establishing Neuraxpharm as a CNS specialist in the North West European country
With Tom Coogan, Neuraxpharm can count on a dedicated entrepreneur with highly relevant market expertise. It has proven itself in the successful construction of the Ireland company of Grünenthal Pharma SA (Grünenthal) to become a leading player in Ireland in the field of pain management and related diseases. At Neuraxpharm, he will focus on advancing the company’s position in Ireland applying his deep expertise of the Irish market to strategically grow the business and ensure the successful development of the product portfolio in line with that of the Group.
Tom Coogan combines a strong start-up spirit with almost thirty years of experience in the pharmaceutical industry. He joins Neuraxpharm from Grünenthal, where he most recently held the position of Managing Director. Since 2004 he has successfully built the Grünenthal’s Ireland company to become one of the top 20 pharmaceutical companies in Ireland. Tom Coogan was National Sales Manager at Lundbeck Ireland from 2001 to 2004, having held positions as CNS Hospital Specialist at Organon from 1999 to 2001 and Hospital Representative at Upjohn from 1993 to 1998.
Dr Jörg-Thomas DierksCEO of Neuraxpharm, said: “We are very pleased to announce the appointment of Tom Coogan as the new Country Manager for Ireland. We are confident that with his experience and hands-on mentality, Tom will help us elevate our business in Ireland to the next level. I look forward to working with him and together expanding our position as a leading CNS company with a broad and diverse portfolio.”
Tom Coogannewly appointed Country manager for Ireland added: “I am delighted to join Neuraxpharm as Country Manager. With its acquisition of Medinutrix in 2020, Neuraxpharm has become a serious player in the Ireland. I look forward to working with my new team and contributing all my expertise to further develop our business.”
Neuraxpharm established its activities in Ireland in December 2020 through the acquisition of specialty pharmaceutical company Medinutrix (trading as Aribamed) and will leverage its CNS expertise to provide access to tailored products from its extensive portfolio, including the recently acquired Buccolam® for the treatment emergencies for children and adolescents with epilepsy. Tom Coogan will take over from Craig Bowenwho will now focus on his role as managing director of Neuraxpharm UK.
About the Neuraxpharm Group – the European CNS specialist
Neuraxpharm is a leading European pharmaceutical company specializing in the treatment of central nervous system (CNS) disorders with a direct presence in 19 countries. Backed by funds advised by Permira, Neuraxpharm has a unique understanding of the CNS market built over 35 years.
With a focus on the CNS, Neuraxpharm develops and markets value-added drugs, off-the-shelf generics, medical cannabis and consumer health products, e.g. probiotics and other nutraceuticals, and continuously strives to to offer a wide range of effective, high quality and affordable CNS treatments. options in Europe.
Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites, Lesvi and Inke, in Spain.
To learn more about Neuraxpharm, please visit: https://www.neuraxpharm.com
SOURCE Neuraxpharm Group